Development and internal validation of VA-BLED for 1-year esophageal variceal bleeding risk in cirrhosis
PLOS One · 16.11.2026 · 21 (11) · e0362884
DOI: 10.1371/journal.pone.0362884 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift PLOS One, online erschienen am 16.11.2026. Verfasst von Dominic Denk und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine I, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany. Hauptthemen laut MEDLINE: Esophageal and Gastric Varices, Gastrointestinal Hemorrhage, Liver Cirrhosis. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Background and Aims Esophageal variceal bleeding is a life-threatening complication of cirrhosis, yet current risk stratification targets portal hypertension stage and endoscopic stigmata instead of short-term bleeding probability. We evaluated whether a simple score built from routinely available variables could stratify 1-year esophageal variceal bleeding risk.
Methods
We developed and internally validated two multivariable logistic models in a retrospective outcome-balanced cohort of 108 patients with esophageal varices (54 variceal bleeding, 54 no bleeding). VA-BLED BASE incorporated Child-Pugh score, normalized alanine aminotransferase, and current alcohol use. VA-BLED HISTORY additionally incorporated previous bleeding. Performance was assessed from out-of-fold predictions using discrimination, calibration, and decision curve analysis.
Results
VA-BLED BASE achieved an out-of-fold area under the receiver operating characteristic curve of 0.732 (95% confidence interval, 0.635–0.827), which increased to 0.798 (95% confidence interval, 0.705–0.883) when previous bleeding history was included. Both models provided net benefit across clinically plausible threshold probabilities. At an assumed annual bleeding prevalence of 10%, VA-BLED BASE generated low-, intermediate-, and high-risk zones, whereas VA-BLED HISTORY functioned primarily as a high-risk enrichment model.
Conclusions
In this proof-of-concept development study, VA-BLED BASE and VA-BLED HISTORY stratified 1-year EVB risk using routinely available clinical variables and identified subgroups enriched for bleeding events. External validation in cohort-design populations is required before clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medicine I, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
- Laboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, University of California San Diego, La Jolla, California, United States of America.
- Center for Metabolic and Liver Disease, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, United States of America.
ORCID-Profile: Dominic Denk
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Denk, D., Schröder, S., Friedrich-Rust, M., Zeuzem, S., & Queck, A. (2026). Development and internal validation of VA-BLED for 1-year esophageal variceal bleeding risk in cirrhosis. PLOS One, 21(11), e0362884. https://doi.org/10.1371/journal.pone.0362884
Vancouver
Denk D, Schröder S, Friedrich-Rust M, Zeuzem S, Queck A. Development and internal validation of VA-BLED for 1-year esophageal variceal bleeding risk in cirrhosis. PLOS One. 2026;21(11):e0362884. doi:10.1371/journal.pone.0362884
BibTeX
@article{Denk2026,
author = {Denk, Dominic and Schröder, Silja and Friedrich-Rust, Mireen and Zeuzem, Stefan and Queck, Alexander},
title = {Development and internal validation of VA-BLED for 1-year esophageal variceal bleeding risk in cirrhosis},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {11},
pages = {e0362884},
doi = {10.1371/journal.pone.0362884}
}
EUVIMED